GMP and Chemotherapy Response in Breast Cancer
Author Information
Author(s): Akslen L A, Straume O, Geisler S, Sørlie T, Chi J-T, Aas T, Børresen-Dale A-L, Lønning P E
Primary Institution: The Gade Institute, University of Bergen
Hypothesis
Does glomeruloid microvascular proliferation (GMP) predict lack of response to chemotherapy in breast cancer?
Conclusion
GMP is associated with a lack of response to neoadjuvant chemotherapy in locally advanced breast cancer.
Supporting Evidence
- GMP was present in 21% of the cases studied.
- GMP positivity was significantly associated with high-grade tumors.
- GMP was correlated with TP53 mutations.
- GMP was linked to a gene expression signature for tumor hypoxia response.
- GMP positivity was associated with lack of treatment response and progressive disease.
Takeaway
GMP is a marker that can help doctors understand if breast cancer patients will respond to chemotherapy. If GMP is present, the treatment might not work as well.
Methodology
The study evaluated the presence of GMP in 112 cases of locally advanced breast cancer and its association with treatment response.
Limitations
The study's findings need confirmation in larger studies to establish GMP as an independent predictor.
Participant Demographics
Patients were treated for locally advanced breast cancer, with a median age of 64 years.
Statistical Information
P-Value
0.004
Statistical Significance
p=0.004
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website